[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trichomonas-vaginitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trichomonas-vaginitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100536208","phase-4-refining-treatment-options-for-trichomonas-vaginalis-infection-a-comparative-analysis-of-metronidazole-and-secnidazole-100536208",false,"NCT06261840","Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole","Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole","Inclusion Criteria:\n\n* Women and men aged 18 years or older of any race\u002Fethnicity will be included in the study.\n* Participants must have either a positive T. vaginalis rapid antigen test (OSOM), or wet mount microscopy with motile trichomonads, or nucleic acid amplification test (NAAT) urinalysis or Pap smear positive for TV within two weeks of available results (and have not yet been treated) that is confirmed by repeat T. vaginalis NAAT testing at study enrollment,\n* Willing and able to provide and understand informed consent to comply with the study protocol,\n* Have a method of contact (either phone, email or social media),\n* Be willing to be randomized.\n\nExclusion Criteria:\n\n* Pregnant\u002Flactating or seeking to be pregnant\n* Have been treated for with a 5-nitroimidazole (i.e. Metronidazole (MTZ), tinidazole (TDZ), or secnidazole \\[SEC\\]) in the last 28 days\n* Used intravaginal boric acid or any other intravaginal treatment for T. vaginalis in the last 14 days\n* Have a history of a type 1 hypersensitivity reaction to 5-nitroimidazole medications\n* Are taking phenytoin (Dilantin) and\u002For warfarin (Coumadin) due to drug-drug interactions with oral MTZ\n* Use of medications which may alter the metabolism of MTZ including Lithium and barbiturates (amobarbital, butalbital, methohexital, phenobarbital, pentobarbital, primidone, secobarbital)\n* Have been previously enrolled in the study",true,"ALL","18 Years",{"count":20,"type":21},1200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.",[27,28],"Trichomonas Vaginitis","Bacterial Vaginitis","RECRUITING","2026-05-04",{"date":32,"type":33},"2026-05-06","ACTUAL",{"date":35,"type":33},"2025-05-06",{"date":37,"type":21},"2029-07-31",{"name":39,"class":40},"Tulane University","OTHER",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100468725","safety-and-efficacy-of-two-oral-tinidazole-regimens-for-refractory-trichomonas-vaginitis-100468725","NCT05383521","Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis","Oral Tinidazole Treatment of Refractory Trichomonas Vaginitis","Inclusion Criteria:\n\n* Women be at least 18 years of age\n* Failure of conventional treatment (recommended by guidelines including tinidazole, 2g once daily for 5-7 days)\n\nExclusion Criteria:\n\n* Allergy to metronidazole or tinidazol\n* Pregnant or nursing\n* HIV or other chronic disease","FEMALE","55 Years",{"count":52,"type":21},20,[54],"NA","We compare two oral tinidazole regimens for refractory trichomonas vaginitis.",[27],[58,59],"Refractory Trichomonas Vaginitis","Tinidazole","NOT_YET_RECRUITING","2024-06-08",{"date":63,"type":33},"2024-06-11",{"date":65,"type":21},"2025-12-01",{"date":67,"type":21},"2025-12-30",{"name":69,"class":40},"Shangrong Fan"]